Customize your JAMA Network experience by selecting one or more topics from the list below.
Stüve and colleagues review recent experience with natalizumab therapy for multiple sclerosis. Three patients who were treated with natalizumab developed progressive multifocal leukoencephalopathy (PML). The pathogenesis of natalizumab-associated PML may be different from that of non–natalizumab-associated PML. There are currently no treatment guidelines for patients receiving natalizumab therapy who might develop PML or other infections. They discuss incisively the biologically feasible potential interventions for patients diagnosed with PML or other infections while receiving natalizumab therapy.
Keane presents his review of the causes of bilateral ocular paralysis. He reports that Fisher syndrome (13 cases) and Guillain-Barré syndrome (5 cases) compose 58% of the 31 cases described.
This Month in Archives of Neurology. Arch Neurol. 2007;64(2):162–163. doi:https://doi.org/10.1001/archneur.64.2.162
Create a personal account or sign in to: